drugset / Trial / NCT05018728
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
NaSingle-groupOpen-labelSupportive care
Summary
Voxelotor is a new drug for adolescents and adults with sickle cell disease that improves hemoglobin levels and reduces the incidence of worsening anemia. However, it is unclear whether this increase in hemoglobin is associated with a reduction in cerebral metabolic stress. This study will measure the effects of voxelotor on cerebral hemodynamics.
Timeline
- Start
- 2022-03-28
- Primary completion
- 2024-10-22
- Completion
- 2024-10-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Voxelotor | Small molecule | 1500 mg | Oral |